Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Regeneron Pharmaceuticals Inc patents


Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors


Room temperature stable lyophilized protein

Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of... Regeneron Pharmaceuticals Inc

Anti-prlr antibodies and uses thereof

The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments,... Regeneron Pharmaceuticals Inc

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition... Regeneron Pharmaceuticals Inc

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition... Regeneron Pharmaceuticals Inc

Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus

A non-human animal (e.g., a rodent) model for diseases associated with a C9ORF72 heterologous hexanucleotide repeat expansion sequence is provided, which non-human animal comprises a heterologous hexanucleotide repeat (GGGGCC) in an endogenous C9ORF72 locus. A non-human animal disclosed herein comprising a heterologous hexanucleotide repeat expansion sequence comprising at least one... Regeneron Pharmaceuticals Inc

Humanized t cell co-receptor mice

The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8α, CD8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.... Regeneron Pharmaceuticals Inc

Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present... Regeneron Pharmaceuticals Inc

Human lambda light chain mice

Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an... Regeneron Pharmaceuticals Inc

Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

The present invention provides anti-Gremlin-1 (GREM1) antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH).... Regeneron Pharmaceuticals Inc

Anti-il-25 antibodies and uses thereof

The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies... Regeneron Pharmaceuticals Inc

Genetically modified non-human animals and methods of use thereof

Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses... Regeneron Pharmaceuticals Inc

Modified chimeric polypeptides with improved pharmacokinetic properties

The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.... Regeneron Pharmaceuticals Inc

Stabilized formulations containing anti-pcsk9 antibodies

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of... Regeneron Pharmaceuticals Inc

Anti-egfr antibodies and uses thereof

The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth... Regeneron Pharmaceuticals Inc

Anti-erbb3 antibodies and uses thereof

The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand... Regeneron Pharmaceuticals Inc

Nuclease-mediated targeting with large targeting vectors

Compositions and methods are provided for making one or more targeted genetic modifications at a target genomic locus by employing homologous recombination facilitated by single or double-strand break at or near the target genomic locus. Compositions and methods for promoting efficiency of homologous recombination between an LTVEC and a target... Regeneron Pharmaceuticals Inc

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

Provided are non-human animals comprising a mutation in the Fbn1 gene to model neonatal progeroid syndrome with congenital lipodystrophy (NPSCL). Also provided are methods of making such non-human animal models. The non-human animal models can be used for screening compounds for activity in inhibiting or reducing NPSCL or ameliorating NPSCL-like... Regeneron Pharmaceuticals Inc

Apelin fusion proteins and uses thereof

The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion... Regeneron Pharmaceuticals Inc

Gpr156 variants and uses thereof

The disclosure provides nucleic acids, including cDNA, comprising alterations that encode aspartic acid at a position corresponding to position 533 of the human G protein-coupled receptor 156 protein (GPR156). The disclosure also provides isolated and recombinant human GPR156 protein variants that comprise an aspartic acid at a position corresponding to... Regeneron Pharmaceuticals Inc

Novel cho integration sites and uses thereof

Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and... Regeneron Pharmaceuticals Inc

Genetically modified non-human animals and methods of use thereof

The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.... Regeneron Pharmaceuticals Inc

Mice expressing polymorphic low affinity fcgammar alpha-chains

Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low... Regeneron Pharmaceuticals Inc

Anti-zika virus antibodies and methods of use

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. In... Regeneron Pharmaceuticals Inc

Methods for treating or preventing asthma by administering an il-4r antagonist

The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.... Regeneron Pharmaceuticals Inc

Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension

The present invention provides anti-Activin A antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH).... Regeneron Pharmaceuticals Inc

Humanized il-4 and il-4ra animals

Non-human animals comprising a human or humanized IL-4 and/or IL-4Rα nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous IL-4 gene and/or IL-4Rα gene with a human IL-4 gene and/or IL-4Rα gene in whole or in part, and methods for making and using the non-human... Regeneron Pharmaceuticals Inc

Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention... Regeneron Pharmaceuticals Inc

Nuclease-mediated dna assembly

Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order... Regeneron Pharmaceuticals Inc

Non-human animals expressing ph-sensitive immunoglobulin sequences

Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon... Regeneron Pharmaceuticals Inc

Mice expressing a limited immunoglobulin light chain repertoire

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse... Regeneron Pharmaceuticals Inc

Animal model for dry eye and methods of use of such animals

Provided herein are methods for creating an animal model for the study of dry eye and methods of using such animal models to test candidate treatments for ocular conditions and determine the efficacy of such treatments.... Regeneron Pharmaceuticals Inc

Vegf antagonist formulations

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.... Regeneron Pharmaceuticals Inc

Human antibodies to ebola virus glycoprotein

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection... Regeneron Pharmaceuticals Inc

Anti-c5 antibodies and uses thereof

The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or... Regeneron Pharmaceuticals Inc

Anti-gitr antibodies and uses thereof

Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR) and methods of using the same, including, e.g., methods of treatment using the same.... Regeneron Pharmaceuticals Inc

12/07/17 / #20170347633

Non-human animals expressing exogenous terminal deoxynucleotidyltransferase

Provided herein are methods and compositions related to non-human animals that express exogenous Terminal Deoxynucleotidyltransferase (TdT).... Regeneron Pharmaceuticals Inc

11/30/17 / #20170340728

Human antibodies to middle east respiratory syndrome - coronavirus spike protein

The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for... Regeneron Pharmaceuticals Inc

11/23/17 / #20170332609

Humanized light chain mice

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light... Regeneron Pharmaceuticals Inc

11/23/17 / #20170332610

Methods for breaking immunological tolerance using multiple guide rnas

Methods and compositions are provided for making non-human animals with reduced tolerance of a foreign antigen of interest and making antigen-binding proteins against that foreign antigen of interest using such animals. The methods and compositions employ CRISPR/Cas9 systems using multiple guide RNAs to reduce or eliminate expression of a self-antigen... Regeneron Pharmaceuticals Inc

11/23/17 / #20170332611

Humanized c5 animals

Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or... Regeneron Pharmaceuticals Inc

11/23/17 / #20170333557

Methods for treating atopic dermatitis by administering an il-4r antagonist

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject... Regeneron Pharmaceuticals Inc

11/23/17 / #20170335341

Efficient selectivity of recombinant proteins

The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention... Regeneron Pharmaceuticals Inc

11/16/17 / #20170327567

Combination of anti-pd-1 antibodies and radiation to treat cancer

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., solid tumors). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), optionally, in... Regeneron Pharmaceuticals Inc

11/16/17 / #20170327590

Methods of treating skin cancer by administering a pd-1 inhibitor

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain... Regeneron Pharmaceuticals Inc

11/16/17 / #20170327593

Method for generating high affinity antibodies

The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized... Regeneron Pharmaceuticals Inc

11/09/17 / #20170320948

Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor... Regeneron Pharmaceuticals Inc

11/02/17 / #20170311580

Humanized il-4 and il-4ra animals

Non-human animals comprising a human or humanized IL-4 and/or IL-4Rα nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous IL-4 gene and/or IL-4Rα gene with a human IL-4 gene and/or IL-4Rα gene in whole or in part, and methods for making and using the non-human... Regeneron Pharmaceuticals Inc

11/02/17 / #20170311581

Humanized il-7 rodents

Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or... Regeneron Pharmaceuticals Inc

11/02/17 / #20170312359

Methods for treating patients with familial hypercholesterolemia

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to... Regeneron Pharmaceuticals Inc

10/26/17 / #20170308642

Non-hypergeometric overlap probability

Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that... Regeneron Pharmaceuticals Inc

10/19/17 / #20170295762

Methods and compositions for generating a mouse

Methods of generating modified embryos and mammals by introduction of donor cells into an early stage embryo are provided, such that the resulting embryo and animal generated therefrom has a significant contribution to all tissues from the donor cells and is capable of transmitting the donor cell DNA.... Regeneron Pharmaceuticals Inc

10/19/17 / #20170296657

Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9

The present invention provides methods for treating hypercholesterolemia and reducing LDL-C. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.... Regeneron Pharmaceuticals Inc

10/12/17 / #20170290308

Rodents having a humanized tmprss gene

Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.... Regeneron Pharmaceuticals Inc

10/12/17 / #20170291937

Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor

The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically... Regeneron Pharmaceuticals Inc

10/12/17 / #20170291938

Production cell line enhancers

The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2.... Regeneron Pharmaceuticals Inc

10/05/17 / #20170281725

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression... Regeneron Pharmaceuticals Inc

10/05/17 / #20170286594

Genetic variant-phenotype analysis system and methods of use

Methods and systems for generating and analyzing genetic variant-phenotype association results are disclosed.... Regeneron Pharmaceuticals Inc

09/28/17 / #20170273285

Humanized m-csf mice

Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice.... Regeneron Pharmaceuticals Inc

09/28/17 / #20170273286

Genetically modified major histocompatibility complex animals

The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the humanized MHC II protein. Also provided are constructs for making, and methods of making, the genetically modified non-human animals. Methods... Regeneron Pharmaceuticals Inc

09/21/17 / #20170265442

Non-human animals having a humanized signal-regulatory protein gene

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized... Regeneron Pharmaceuticals Inc

09/14/17 / #20170258059

Human lambda light chain mice

Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an... Regeneron Pharmaceuticals Inc

09/14/17 / #20170260293

Multivalent antigen-binding proteins

Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that... Regeneron Pharmaceuticals Inc

09/14/17 / #20170260544

Compositions and methods for modifying cells

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically... Regeneron Pharmaceuticals Inc

09/07/17 / #20170252434

Compositions for improving the health related quality of life of rheumatoid arthritis patients

The present invention provides compositions and methods of for improving the Health-Related Quality of Life of a subject suffering from rheumatoid arthritis, comprising administering to the subject an effective amount of sarilumab.... Regeneron Pharmaceuticals Inc

09/07/17 / #20170253666

Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically... Regeneron Pharmaceuticals Inc

Patent Packs
08/31/17 / #20170245481

Non-human animals having a engineered angptl8 gene

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an Angiopoietin-like protein 8 (ANGPTL8) gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous ANGPTL8 locus so that said... Regeneron Pharmaceuticals Inc

08/31/17 / #20170245482

Rodents having a humanized tmprss gene

Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.... Regeneron Pharmaceuticals Inc

08/31/17 / #20170247436

Non-human animals having a mutant kynureninase gene

Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a mutant L-kynurenine hydrolase (or kynureninase) gene. Said non-human animals may be described, in some embodiments, as having a genetic modification in an endogenous kynureninase gene so that said non-human animals express... Regeneron Pharmaceuticals Inc

08/31/17 / #20170247474

Multivalent antigen-binding proteins

Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that... Regeneron Pharmaceuticals Inc

08/24/17 / #20170239342

Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need... Regeneron Pharmaceuticals Inc

08/24/17 / #20170241887

Isolating cells expressing secreted proteins

A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with... Regeneron Pharmaceuticals Inc

08/17/17 / #20170233466

Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3

The present invention provides methods and compositions for treating or preventing atherosclerosis in a subject. The methods of the present invention comprise administering an inhibitor of angiopoietin-like protein-3 (ANGPTL3) to a subject who has atherosclerosis or is at risk of developing atherosclerosis. In certain embodiments, the ANGPTL3 inhibitor is an... Regeneron Pharmaceuticals Inc

08/17/17 / #20170233806

Methods and systems for detection of abnormal karyotypes

Methods and systems for detecting abnormal karyotypes are disclosed. An example method can comprise determining read coverage data, allele balance distributions of heterozygous SNPs, and chromosomal segments where heterozygosity is not observed. The methods and systems can then determine one or more metrics which can be indicative of abnormal karyotype(s).... Regeneron Pharmaceuticals Inc

08/10/17 / #20170223939

Mice that make vl binding proteins

Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light... Regeneron Pharmaceuticals Inc

08/10/17 / #20170226197

Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a

The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other... Regeneron Pharmaceuticals Inc

08/10/17 / #20170226231

Mice that make vl binding proteins

Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light... Regeneron Pharmaceuticals Inc

08/03/17 / #20170218065

Anti-glucagon antibodies and uses thereof

The present invention provides antibodies that bind to glucagon and methods of using the same. According to certain embodiments, the antibodies of the invention bind human GCG with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment... Regeneron Pharmaceuticals Inc

08/03/17 / #20170218399

Production of fertile xy female animals from xy es cells

Methods and compositions are described for making phenotypically female fertile animals from XY donor cells and suitable host embryos. Culture media and methods are provided for maintaining XY donor cells in culture that after introduction into a host embryo and gestation in a suitable host will result in fertile XY... Regeneron Pharmaceuticals Inc

07/27/17 / #20170210800

Aplnr modulators and uses thereof

The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that... Regeneron Pharmaceuticals Inc

07/27/17 / #20170209591

Maytansinoid derivatives, conjugates thereof, and methods of use

Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.... Regeneron Pharmaceuticals Inc

Patent Packs
07/27/17 / #20170210790

Human antibodies to fel d1 and methods of use thereof

The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of... Regeneron Pharmaceuticals Inc

07/27/17 / #20170210813

Anti-pdgfr-beta antibodies and uses thereof

The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for... Regeneron Pharmaceuticals Inc

07/27/17 / #20170211099

Methods and compositions for modifying a targeted locus

Methods and compositions are provided for modifying one or more target loci in a cell. Such methods comprise providing a cell comprising a first polynucleotide encoding a first selection marker operably linked to a first promoter active in the cell, wherein the first polynucleotide further comprises a first recognition site... Regeneron Pharmaceuticals Inc

07/27/17 / #20170211115

Fucosylation-deficient cells

An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are... Regeneron Pharmaceuticals Inc

07/20/17 / #20170202911

Use of a vegf antagonist to treat angiogenic eye disorders

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more... Regeneron Pharmaceuticals Inc

07/20/17 / #20170204430

Targeted modification of rat genome

Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are... Regeneron Pharmaceuticals Inc

07/06/17 / #20170188556

Non-human animals having a humanized b-cell activating factor gene

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.... Regeneron Pharmaceuticals Inc

07/06/17 / #20170191014

Systems and trays for processing samples by a robotic platform

A system for processing samples by a robotic platform has a tray that defines a well defining a drain. The well has a bottom surface, an access port in fluid communication with the drain, and an insert adapted to be received in the well. The insert has a bottom wall... Regeneron Pharmaceuticals Inc

07/06/17 / #20170191101

Clarification of mammalian cell culture

Disclosed is an improved method for clarifying a cell culture during the manufacture of a protein. The method includes the step of transiently reducing the pH of a cell culture, followed by a holding step for a period of time, followed by the neutralization of the cell culture prior to... Regeneron Pharmaceuticals Inc

06/29/17 / #20170181978

Polymer protein microparticles

Microparticles containing a core of therapeutic protein and a cortex of a biocompatible and biodegradable polymer, and methods of making and using the microparticles are provided. The extended release of a therapeutic protein from the microparticles in a physiological solution is demonstrated over an extended period of time.... Regeneron Pharmaceuticals Inc

06/22/17 / #20170172121

Genetically modified mice and engraftment

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mll2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/ll2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174769

Fgf21 receptor agonists and uses thereof

The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding βKlotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174779

Combination of anti-pd-1 antibodies and anti-cd20/anti-cd3 antibodies to treat cancer

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174781

Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of acute lymphoblastic leukemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174789

Anti-tie2 antibodies and uses thereof

The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin... Regeneron Pharmaceuticals Inc

06/15/17 / #20170164588

Non-human animals expressing humanized cd3 complex

Non-human animals, expressing humanized CD3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized CD3 proteins are also provided. Additionally, provided are methods and compositions of making such non-human animals, as well as methods of using said non-human animals.... Regeneron Pharmaceuticals Inc

06/15/17 / #20170164590

Genetically modified major histocompatibility complex mice

The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using... Regeneron Pharmaceuticals Inc

06/15/17 / #20170166646

Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).... Regeneron Pharmaceuticals Inc

05/25/17 / #20170142943

Non-human animals having a humanized lymphocyte-activation gene 3

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that said... Regeneron Pharmaceuticals Inc

05/25/17 / #20170142944

Genetically modified major histocompatibility complex animals

The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using... Regeneron Pharmaceuticals Inc

05/18/17 / #20170135326
05/18/17 / #20170135329

Genetically modified major histocompatibility complex mice

The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using... Regeneron Pharmaceuticals Inc

05/18/17 / #20170136090

Angiopoietin-based interventions for treating cerebral malaria

The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.... Regeneron Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###